<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00902031</url>
  </required_header>
  <id_info>
    <org_study_id>G599001036</org_study_id>
    <secondary_id>G517000014</secondary_id>
    <nct_id>NCT00902031</nct_id>
  </id_info>
  <brief_title>Effectiveness of Docusate in Preventing/Treating Constipation in Palliative Care Patients</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Trial of Oral Docusate for Preventing/Treating Constipation in Palliative Care Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>College of Family Physicians of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Covenant Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Capital Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if docusate is effective in the treatment of&#xD;
      constipation in palliative care patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Palliative patients frequently experience constipation due to multiple factors - structural&#xD;
      abnormalities, medications, metabolic disturbances, neurological disorders, and other general&#xD;
      conditions. Docusate is a stool softener that has been widely used, in combination with other&#xD;
      stimulating laxatives, to prevent and treat constipation in palliative care patients. In the&#xD;
      past decade there has been controversy about its effectiveness in these populations, but no&#xD;
      controlled trials have been conducted on the use of docusate in palliative patients. The&#xD;
      purpose of this study is to assess the effectiveness of docusate in preventing and treating&#xD;
      constipation in palliative care patients. The study design is a randomized, double-blind,&#xD;
      placebo-controlled trial to compare the current standard treatment (docusate in combination&#xD;
      with a laxative, sennoside) to that of a sennoside laxative alone. A total of 70 patients (35&#xD;
      in each group) will be recruited from the Palliative Care Unit at St. Joseph's Auxiliary Care&#xD;
      Hospital, the Mel Miller Hospice at the Edmonton General Continuing Care Hospital, and&#xD;
      CapitalCare Norwood in Edmonton, Alberta, Canada. Patients must be ≥ 18 years of age, able to&#xD;
      take oral medication, without difficulty swallowing, have a palliative performance ≥ 20%, and&#xD;
      do not have a stoma. The duration of treatment will be for 10 days. The main outcome measures&#xD;
      will include bowel frequency, stool consistency, other interventions (suppositories, enemas),&#xD;
      difficulty defecating, and sense of inability to evacuate completely. This study will provide&#xD;
      insight into the effectiveness of docusate in preventing and treating constipation in&#xD;
      palliative patients who are cared for by family physicians and specialized palliative care&#xD;
      providers. If docusate is found to have no added benefit,it has the potential to enhance the&#xD;
      quality of life for palliative care patients by reducing the number of medications taken and&#xD;
      reducing the palliative care team's (e.g. nursing) workload and cost.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stool Frequency</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stool Consistency</measure>
    <time_frame>10 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Difficulty Defecating</measure>
    <time_frame>10 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms Related to Constipation (pain, nausea, appetite loss, abdominal discomfort, shortness of breath)</measure>
    <time_frame>10 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of Additional Bowel Care Interventions which may be Required</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Constipation</condition>
  <condition>Palliative Care</condition>
  <arm_group>
    <arm_group_label>Docusate + Sennoside</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sennoside + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docusate Sodium, Sennoside</intervention_name>
    <description>Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.&#xD;
Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.</description>
    <arm_group_label>Docusate + Sennoside</arm_group_label>
    <other_name>Colace</other_name>
    <other_name>Senokot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sennoside + Placebo</intervention_name>
    <description>Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.&#xD;
Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days</description>
    <arm_group_label>Sennoside + Placebo</arm_group_label>
    <other_name>Senokot</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  greater than or equal to 18 years of age&#xD;
&#xD;
          -  new admissions&#xD;
&#xD;
          -  able to take oral medications&#xD;
&#xD;
          -  patient and/or personal directive agent (proxy) provides written consent&#xD;
&#xD;
          -  does not have a stoma&#xD;
&#xD;
          -  no difficulty swallowing&#xD;
&#xD;
          -  no previous intolerance/contraindications to docusate&#xD;
&#xD;
          -  palliative performance greater than or equal to 20%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  less than 18 years of age&#xD;
&#xD;
          -  failing to provide consent&#xD;
&#xD;
          -  unable to take oral medication/difficulty swallowing&#xD;
&#xD;
          -  previous intolerance/contraindications to docusate (Colace)&#xD;
&#xD;
          -  patients who have a stoma&#xD;
&#xD;
          -  palliative performance status &lt; 20%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Spooner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoko Tarumi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta/Regional Palliatvie Care Program (Capital Health)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Szafran, MSc.</last_name>
    <role>Study Director</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CapitalCare Norwood</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5G 3A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mel Miller Hospice at Edmonton General Continuing Care Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 0A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Auxiliary Care Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6J 6W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>CASS LJ, FREDERIK WS. Doxinate in the treatment of constipation. Am J Gastroenterol. 1956 Dec;26(6):691-8.</citation>
    <PMID>13372512</PMID>
  </reference>
  <reference>
    <citation>Castle SC, Cantrell M, Israel DS, Samuelson MJ. Constipation prevention: empiric use of stool softeners questioned. Geriatrics. 1991 Nov;46(11):84-6.</citation>
    <PMID>1718823</PMID>
  </reference>
  <reference>
    <citation>Fain AM, Susat R, Herring M, Dorton K. Treatment of constipation in geriatric and chronically ill patients: a comparison. South Med J. 1978 Jun;71(6):677-80.</citation>
    <PMID>78527</PMID>
  </reference>
  <reference>
    <citation>Goodman J, Pang J, Bessman AN. Dioctyl sodium sulfosuccinate- an ineffective prophylactic laxative. J Chronic Dis. 1976 Jan;29(1):59-63.</citation>
    <PMID>1254685</PMID>
  </reference>
  <reference>
    <citation>Hurdon V, Viola R, Schroder C. How useful is docusate in patients at risk for constipation? A systematic review of the evidence in the chronically ill. J Pain Symptom Manage. 2000 Feb;19(2):130-6.</citation>
    <PMID>10699540</PMID>
  </reference>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>May 13, 2009</study_first_submitted>
  <study_first_submitted_qc>May 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2009</study_first_posted>
  <last_update_submitted>April 19, 2011</last_update_submitted>
  <last_update_submitted_qc>April 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Richard Spooner</name_title>
    <organization>University of Alberta</organization>
  </responsible_party>
  <keyword>Docusate</keyword>
  <keyword>Constipation</keyword>
  <keyword>Colace</keyword>
  <keyword>Palliative Care</keyword>
  <keyword>Sennoside</keyword>
  <keyword>Senokot</keyword>
  <keyword>Terminally Ill</keyword>
  <keyword>Stool</keyword>
  <keyword>Randomized Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bismuth subsalicylate</mesh_term>
    <mesh_term>Sennosides</mesh_term>
    <mesh_term>Senna Extract</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

